GRI Bio's IPF Drug Shows Promising Tolerability in Phase 2a Trial
Event summary
- GRI Bio's GRI-0621 showed zero cough and 60% lower treatment-related diarrhea than placebo in Phase 2a IPF trial.
- Company reported $11.0 million in cash as of March 31, 2026, sufficient for operations into Q2 2027.
- GRI-0803 advanced toward IND-enabling activities for autoimmune indications.
- First quarter 2026 R&D expenses decreased to $0.4 million from $1.6 million in 2025.
- Net loss for Q1 2026 was $2.0 million, down from $3.0 million in Q1 2025.
The big picture
GRI Bio's Phase 2a data for GRI-0621 in IPF highlights the potential to mitigate common side effects of current therapies, addressing a significant unmet need. The company's progress in advancing its pipeline and strengthening its balance sheet positions it within the competitive landscape of inflammatory and autoimmune disease treatments. The strategic focus on NKT cell modulation differentiates GRI Bio in a market driven by innovative immune-modulating therapies.
What we're watching
- Clinical Efficacy
- Whether GRI-0621's tolerability benefits will translate into long-term clinical efficacy in IPF patients.
- Regulatory Pathway
- The pace at which GRI Bio advances GRI-0621 toward pivotal studies and secures regulatory approvals.
- Financial Sustainability
- How GRI Bio will manage its cash runway and secure additional funding for Phase 2b trials.
Related topics